Soft tissue targets: muscle, tendon, fascia, skin
Autologous regenerative therapy based on micro-fragmented adipose tissue and stromal vascular fraction (SVF) has been developed as a versatile platform for the treatment of multiple mesenchymal and soft tissue structures. Adipose-derived mesenchymal stromal/stem cells (ASCs) isolated from the SVF display multipotent differentiation capacity towards osteogenic, chondrogenic, myogenic, hepatogenic and endothelial lineages, indicating a theoretical applicability to a broad spectrum of musculoskeletal and soft tissue targets, including muscle and tendon. The presence of adipocyte progenitors, pericytes and endothelial progenitor cells within the SVF further supports its use in tissues where vascular support and stromal remodeling are central to repair.
In clinical and translational practice, a major focus of autologous adipose-derived therapies has been on skin and subcutaneous tissues. The implantation of adipose tissue rich in SVF and ASCs has been used to improve skin trophism, accelerate closure of complex wounds or ulcers, and enhance the appearance of skin damaged by radiotherapy. These applications position the skin and its supporting fascia and subcutaneous fat as primary soft tissue targets for autologous stromal-based interventions. The combination of volumetric support from viable adipocytes and the regenerative influence of SVF/ASCs underpins their use in aesthetic rejuvenation and reparative dermatologic indications.
Facial soft tissues represent a paradigmatic field in which autologous adipose-derived therapies are applied to skin, subcutaneous fat and fascial planes. The Superficial Enhanced Fluid Fat Injection (SEFFI) and micro-SEFFI techniques were specifically designed to harvest and deliver adipose tissue with high content of viable adipocytes and stromal cells for facial rejuvenation, targeting areas with both thick and thin skin. By using cannulas with small side portholes (0.8, 0.5 and 0.3 mm), these systems generate micrografts suitable for superficial (subdermal) injection, allowing treatment of the dermal–subdermal interface and the overlying cutaneous envelope.
Beyond the face, micro-fragmented adipose tissue has been proposed as a promising source for regenerative treatments of mesenchymal tissues more broadly, including those involved in degenerative diseases or disorders not adequately managed by conventional care. Clinical studies cited in this context include applications in osteoarthritis, where intra-articular injection of autologous adipose-derived SVF and micro-fragmented fat targets articular cartilage and periarticular soft tissues, and gynecologic conditions such as genitourinary syndrome of menopause, where local soft tissue regeneration is sought. Although the primary documented clinical targets are joints and skin, the underlying biology of ASCs and SVF suggests potential relevance for muscle, tendon and fascia as components of the broader mesenchymal tissue spectrum.
Regenerative potential of stromal fractions
The stromal vascular fraction of adipose tissue is a heterogeneous cell population that includes adipocyte progenitors, pericytes, endothelial progenitor cells and transit-amplifying cells. Within this fraction, adipose-derived stromal/stem cells (ASCs) represent a multipotent mesenchymal population capable of differentiating towards osteogenic, chondrogenic, myogenic, hepatogenic and endothelial lineages in vitro and in vivo. ASCs are abundant in adipose tissue, accounting for approximately 1% of cells, and are characterized by adherence to plastic, expression of mesodermal markers (CD73, CD90, CD105) and absence of hematopoietic markers (CD14, CD34, CD45). These features support their use as a regenerative cell source in autologous therapies.
Beyond differentiation, ASCs and the broader SVF exert important paracrine and immunomodulatory effects. They secrete bioactive molecules that stimulate angiogenesis and revascularization of fat grafts, and exhibit antifibrotic, anti-apoptotic and immunomodulatory properties. These characteristics are implicated in clinical observations such as improved skin trophism, accelerated closure of complex wounds or ulcers, and enhanced skin appearance after radiotherapy damage following adipose tissue grafting. The combination of structural support and biologically active stromal fractions is therefore central to the regenerative potential of autologous adipose-derived therapies.
The method of harvesting and processing adipose tissue influences the quality and viability of the stromal fraction. Studies comparing microcannula-based harvesting (0.8 and 1 mm side port holes) with standard liposuction followed by enzymatic digestion have shown that guided harvesting with small cannulas yields adipose tissue with a comparable amount of viable cells to enzymatically processed tissue. Cell viability remained high immediately after plating and at 72 hours, and an increase in cell viability was observed across all conditions, supporting the concept that minimally invasive, minimally manipulated micro-fragmented adipose tissue can serve as a robust source of viable stromal cells for regenerative applications.
In the context of facial rejuvenation, SEFFI and micro-SEFFI systems have been analytically characterized to confirm their ability to deliver stromal fractions with regenerative potential. Microscopy and Celector-based analyses demonstrated that micro-SEFFI-derived tissue, despite smaller cluster size and lower overall cellularity, still allowed isolation of ASCs with good proliferation rates and differentiation capacity towards mesenchymal lineages. ASCs isolated from adipose tissue harvested with SEFFI and micro-SEFFI cannulas formed colony-forming units and differentiated into adipogenic, osteogenic and chondrogenic lineages, confirming preservation of stemness across different harvesting configurations. These findings support the use of mechanically processed micrografts as a practical means of delivering regenerative stromal fractions in clinical settings.
Repair mechanisms and remodeling
Autologous regenerative therapy (ART) using adipose-derived stromal fractions is conceived to regenerate injured tissues or stimulate their repair through mechanisms that mirror principles of tissue engineering. The approach utilizes autologous mesenchymal stem cells in a single medical procedure, relying on their capacity to respond to local environmental signals and growth factors. Mesenchymal cells, including ASCs, can differentiate according to cues from the surrounding microenvironment, making them suitable for addressing lesions in diverse tissues such as cartilage, tendons and bone.
In addition to lineage differentiation, ASCs contribute to tissue repair through secretion of growth factors and production of new extracellular matrix (ECM) components. These activities support angiogenesis, revascularization of grafted tissue and modulation of local inflammation. The antifibrotic and anti-apoptotic properties of ASCs may counteract pathological remodeling processes, while their immunomodulatory effects can influence the inflammatory milieu in chronic degenerative conditions. Collectively, these mechanisms underpin observed improvements in skin quality, wound healing and joint function following autologous adipose-derived interventions.
The structural characteristics of the grafted adipose tissue also influence remodeling. Micrografts with cluster sizes below 1 mm have been advocated to improve vascularization and facilitate superficial injections, particularly in facial applications. The use of cannulas with small side portholes in SEFFI and micro-SEFFI systems yields tissue with high fluidity and a composition that includes cell aggregates and extracellular matrix fragments, as shown by Celector analysis. These properties may favor integration of the graft into host tissues, distribution within the subdermal plane and sustained delivery of stromal cells and paracrine factors.
In osteoarthritis, intra-articular injection of autologous adipose-derived SVF and micro-fragmented fat is proposed to modulate the imbalance between repair and degeneration in joints characterized by poor intrinsic healing capacity. The regenerative effect is attributed to ADSCs, cytokines, growth factors, pre-adipocytes and mature adipocytes present in the graft, which together may support cartilage homeostasis, reduce inflammation and enhance joint lubrication. Clinical observations of progressive pain reduction and improved range of motion over months after treatment suggest a time-dependent remodeling process, consistent with gradual tissue adaptation and integration of the autologous graft.
Clinical evidence in soft tissue healing
Clinical experience with autologous adipose-derived therapies spans multiple indications, with a substantial body of work in osteoarthritis and cutaneous rejuvenation. In a cohort of patients with hip and knee osteoarthritis treated by intra-articular injection of autologous micro-fragmented adipose tissue using a standardized device, the procedure was described as safe, feasible and minimally invasive, with a session duration of approximately 60–70 minutes. Patients underwent radiologic assessment before treatment and were followed clinically at 1, 3, 6 and 12 months.
In this osteoarthritis cohort, clinical results included increased range of motion and reduced stiffness, with improvements typically emerging around 3 months after treatment. Pain reduction, measured by visual analogue scale (VAS), began at 3 months and reached its peak at 6 months for knees and between 6 and 12 months for hips. Mean preoperative VAS scores around 7.5 decreased to approximately 2.1–2.2 at 6–12 months in knee patients, and similar reductions were observed in hip patients, with mean VAS decreasing from about 7.35 preoperatively to 1.4 at 12 months. These changes were accompanied by functional gains, such as improved performance in sit-to-stand and short walking tests.
Patient-reported outcomes further support the clinical impact of autologous adipose-derived therapy in joint disease. In the same series, 85% of patients reported satisfaction one year after treatment, with notable improvements in pain and quality of life. SF-12 physical and mental component scores indicated favorable health-related quality of life in a substantial proportion of treated individuals. The postoperative course at the donor site was generally uneventful, limited to minimal discomfort, edema and ecchymosis, while the injected joints exhibited only transient swelling and low-grade pain for a few days, with no reported infections or major complications.
In the domain of skin and soft tissue healing, adipose tissue implantation enriched with SVF/ASCs has been associated with improved skin trophism, accelerated closure of complex wounds or ulcers and enhanced appearance of radiotherapy-damaged skin. Micro-fragmented adipose tissue grafts, naturally rich in SVF cells and ADSCs, are considered a valuable approach in aesthetic rejuvenation treatments, providing both volumization and skin regeneration effects. Facial rejuvenation protocols using SEFFI and micro-SEFFI have been reported to correct volume defects and address skin aging in the face and periocular region, combining structural restoration with regenerative benefits, although detailed outcome metrics are not elaborated in the analytical characterization documents. Collectively, these clinical experiences support the role of autologous adipose-derived stromal therapies in soft tissue healing across articular and cutaneous targets.
Treatment indications and outcomes
The principal documented indication for autologous micro-fragmented adipose tissue therapy in the available evidence is mild to moderate osteoarthritis of weight-bearing joints, particularly knees and hips. Patients in the reported cohort presented with initial-stage degenerative osteoarthritis, confirmed by radiographic and MRI evaluation, and were treated with intra-articular injections of autologous fat micrograft processed with a dedicated device. Clinical improvement in terms of pain reduction and joint performance appeared more pronounced in younger patients with lower osteoarthritis grades, suggesting that less advanced disease may be associated with better outcomes.
Outcome measures in this osteoarthritis population included range of motion, stiffness, VAS pain scores and patient-reported quality of life. An average increase of approximately 10 degrees in joint range of motion was observed at 3 months, accompanied by reduced stiffness. VAS scores showed progressive reductions over 3, 6 and 12 months, with the most substantial pain relief at 6 months for knees and 6–12 months for hips. Even in older patients and those with more severe osteoarthritis, pain reduction was reported, although gains in mobility were less marked. A low rate of subsequent joint replacement surgery was noted over longer follow-up, with a minority of patients proceeding to arthroplasty.
In aesthetic and reparative dermatology, indications for autologous adipose-derived stromal therapies include facial aging, volume loss and skin quality impairment. SEFFI and micro-SEFFI techniques are employed to correct facial volume defects and address skin aging of the face and periocular region, using micrografts harvested from superficial adipose layers. The rationale is to achieve natural volumization while leveraging the regenerative properties of SVF/ASCs to improve skin trophism and texture. Micro-fragmented adipose tissue grafts have also been used to enhance healing of complex wounds and ulcers and to improve skin damaged by radiotherapy, reflecting broader indications in soft tissue repair.
Across these indications, safety profiles are consistently favorable. In osteoarthritis treatment, donor site morbidity was limited to transient discomfort, edema and ecchymosis, and no major complications or infections were reported at either donor or recipient sites. The injected material was well tolerated, consistent with its autologous origin. In studies evaluating harvesting and processing techniques, microcannula-based approaches yielded adipose tissue with high cell viability comparable to enzymatically processed samples, supporting their use as minimally invasive, low-manipulation methods compatible with clinical practice. These outcomes collectively support autologous adipose-derived stromal therapies as a treatment option in selected soft tissue and joint conditions, with documented benefits in pain, function and tissue quality.
Integration into clinical pathways
Integration of autologous adipose-derived stromal therapies into clinical pathways requires consideration of procedural logistics, patient selection and alignment with existing treatment algorithms. Autologous regenerative therapy using micro-fragmented adipose tissue is performed as a single-session procedure, encompassing adipose harvesting, processing to obtain SVF-rich micrografts and targeted injection into the affected site. The use of dedicated systems such as SEFFI and micro-SEFFI standardizes harvesting from superficial fat layers with minimal manipulation, facilitating reproducibility and potentially simplifying incorporation into outpatient or day-surgery workflows.
In osteoarthritis management, intra-articular injection of autologous micro-fragmented adipose tissue is positioned among conservative and joint-preserving options. Conventional approaches—physical therapy, weight management, pharmacologic therapies, steroid injections and hyaluronic acid injections—are largely palliative and do not reverse the degenerative process. Autologous adipose-derived stromal therapy offers a biologically oriented intervention aimed at modulating joint homeostasis and supporting tissue repair. Clinical experience suggests that it may be particularly suitable for patients with mild or moderate osteoarthritis, or for those with more severe disease who decline or wish to delay surgical joint replacement.
In aesthetic and reconstructive pathways, SEFFI-based facial rejuvenation can be integrated alongside or in place of traditional volume restoration techniques. The ability of SEFFI and micro-SEFFI to deliver fluid micrografts suitable for superficial injection allows treatment of both deeper and more delicate facial areas within comprehensive rejuvenation strategies that may also include lifting procedures and other minimally invasive interventions. The regenerative component provided by SVF/ASCs aligns with goals of improving skin quality in addition to restoring volume, fitting within multimodal approaches to facial aging.
From a systems perspective, the adoption of autologous adipose-derived therapies is supported by their minimally invasive nature, favorable safety profile and reliance on autologous tissue, which reduces concerns related to immunogenicity. Quality control of harvested tissue, including assessment of cell viability and characterization of stromal fractions, as demonstrated in analytical and comparative studies, provides a framework for standardizing procedures and outcomes. As clinical experience and evidence expand, these therapies can be more precisely positioned within treatment algorithms for osteoarthritis, facial aging and other soft tissue conditions, complementing existing modalities in personalized care pathways.
Sources (Bibliography)
- Trentani P, Meredi E, Zarantonello P, Gennai A. Role of Autologous Micro-Fragmented Adipose Tissue in Osteoarthritis Treatment. Journal of Personalized Medicine, 2024.
- Gennai A, Bovani B, Colli M, Melfa F, Piccolo D, Russo R, Roda B, Zattoni A, Reschiglian P, Zia S. Comparison of Harvesting and Processing Technique for Adipose Tissue Graft: Evaluation of Cell Viability. International Journal of Regenerative Medicine, 2021.
- Gennai A, Bernardini FP. Superficial enhanced fluid fat injection (SEFFI and MicroSEFFI) in facial rejuvenation. CellR4, 2017.
- Bernardini FP, Gennai A, Izzo L, Zambelli A, Repaci E, Baldelli I, Fraternali-Orcioni G, Hartstein ME, Santi PL, Quarto R. Superficial Enhanced Fluid Fat Injection (SEFFI) to correct volume defects and skin aging of the face and periocular region. Aesthetic Surgery Journal, 2015.
- Alviano F, Roda B, Rossi M, et al. Characterization of Tissue and Stromal Cells for Facial Aging Treatment. Aesthetic Surgery Journal, 2020.